<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13965">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02925104</url>
  </required_header>
  <id_info>
    <org_study_id>CINC280A2108</org_study_id>
    <nct_id>NCT02925104</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.</brief_title>
  <official_title>A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose escalation study to assess PK, safety and tolerability of INC280 when taken with food
      in patients with cMET dysregulated advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxiticites (DLTs)</measure>
    <time_frame>During the first 28 days on INC280 treatment; cycle = 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of DLTs</measure>
    <time_frame>During the first 28 days on INC280 treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Category of DLTs</measure>
    <time_frame>During the first 28 days on INC280 treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast for INC280</measure>
    <time_frame>Treatment Cycle 1 Day 1 (C1D1), C1D7, C1D15, C2D1, C3D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau for INC280</measure>
    <time_frame>C1D1, C1D7, C1D15, C2D1, C3D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for INC280</measure>
    <time_frame>C1D1, C1D7, C1D15, C2D1, C3D1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>C1D1, C1D7, C1D15, C2D1, C3D1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events based on CTCAE grading and other safety variables (e.g. EGC readings, physical examination, vital signs and laboratory results).</measure>
    <time_frame>Screening, until 30 days post-treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>cMET Dysegulation Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>INC280</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <arm_group_label>INC280</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  cMET dysregulated advanced solid tumor

          -  At least one measurable lesion as defined by RECIST 1.1

          -  Recovered from all toxicities related to prior anti-cancer therapies to grade ≤ 1

          -  Adequate organ function

          -  ECOG performance status (PS) ≤ 1

        Exclusion Criteria:

          -  Prior treatment with crizotinib or any other cMET or HGF inhibitor

          -  Known hypersensitivity to any of the excipients of INC280

          -  Symptomatic central nervous system (CNS) metastases who are neurologically unstable

          -  Presence or history of a malignant disease other than the study related cancer

          -  Clinically significant, uncontrolled heart diseases

          -  Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 or patients
             who have not recovered from radiotherapy-related toxicities

          -  Major surgery within 4 weeks prior to starting INC280

          -  Impairment of GI function

          -  Patients receiving unstable or increasing doses of corticosteroids

          -  Patients receiving treatment with any enzyme-inducing anticonvulsant

          -  Pregnant or nursing (lactating) women Other protocol-related inclusion/exclusion
             criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 4, 2016</lastchanged_date>
  <firstreceived_date>October 4, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cMET, INC280, food,</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
